China Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in first Hong Kong and subsequently Shanghai to pre-profit biotech companies that meet certain criteria, as well as the reformation and…

China Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China.   From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12 years later, China and its growth story are impossible to ignore. China now accounts for a significant share of revenues…

China China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese characters for ‘returning from overseas’ are homonyms for the Chinese characters for ‘sea turtles’, this influx has ignited the country’s…

China Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in potential candidates for country manager positions in China.   Major Trends among Top Leaders of MNCs in Chinese Pharma Trend…

Opinion Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to China. Consequently, rare diseases now have much more visibility in the country. As an expert on the subject, Kevin breaks…

China What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of  Cornerstone International Group outline what they look for in potential candidates for country manager positions in China.   The Ideal China…

China China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal.   The committee will not be limited to overseeing gene editing alone, but also cover cloning, cell therapy, xenotransplantation, mitochondrial replacement, and nanotechnology The new body, according to reports, will oversee…

China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China.  …

China The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines what he looks for in potential candidates for country manager positions in China.   What are the qualities you look…

China It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four active pharmaceutical ingredients (API’s) by more than 80% in a bid to get new treatments to market faster. Historically, China has…

China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…

China Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the Year of the Pig, 2019.    China approved a record 48 new drugs last year, despite a significant organizational restructuring.…